Cargando…

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

OBJECTIVES: To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gunst, Jesper D, Kjær, Kathrine, Olesen, Rikke, Rasmussen, Thomas A, Østergaard, Lars, Denton, Paul W, Søgaard, Ole S, Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mediscript Ltd 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816120/ https://www.ncbi.nlm.nih.gov/pubmed/31700655

Ejemplares similares

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
por: Chen, Jasmine, et al.
Publicado: (2023)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients
por: Cham, Lamin B., et al.
Publicado: (2021)

Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
por: Andersen, Anna Halling Folkmar, et al.
Publicado: (2020)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
por: Nielsen, Stine SF, et al.
Publicado: (2021)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
por: Vibholm, Line K, et al.
Publicado: (2021)

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
por: Konrad, Christina V., et al.
Publicado: (2023)

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
por: Cham, Lamin B., et al.
Publicado: (2023)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency
por: Zerbato, Jennifer M., et al.
Publicado: (2021)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Persistent Symptoms in Patients Recovering From COVID-19 in Denmark
por: Leth, Steffen, et al.
Publicado: (2021)

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity
por: Rosás-Umbert, Miriam, et al.
Publicado: (2022)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
por: Bullen, C. Korin, et al.
Publicado: (2014)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
por: Schleimann, Mariane H., et al.
Publicado: (2019)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
por: Winckelmann, Anni, et al.
Publicado: (2017)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
por: Falcinelli, Shane D., et al.
Publicado: (2022)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d0777f678j4584vjldact2f5u1